Introduction
Vulvar carcinoma accounts for approximately 5% of gynecologic cancers in the United States with an estimated 4,490 new cases and 950 deaths in 2012 [1] . Survival depends on the extent of cancer spread upon initial diagnosis [2] . The staging of vulvar cancer depends on tumor size and spread to lymph nodes and other organs. Stage I and II comprise the early stages of vulvar carcinoma, where there is localized disease without lymph node involvement. Whereas late stage disease, stage III and IV, involves tumor that has invaded into adjacent structures such as the anus, urethra or vagina as well as metastasized to lymph nodes or other organs.
The majority of vulvar carcinoma are squamous cell in origin and are diagnosed at an early stage [3] . Approximately 32% of cases are still identified in later stages [4] . Treatment for early stage cancer has been well standardized to include wide radical excision of the primary tumor with inguinal-femoral lymphadenectomy or sentinel lymph node biopsy [5] . More advanced lesions involving the anus or rectum may require permanent colostomy, or if the urethra or bladder is involved, urinary diversion might be considered. Unfortunately, radical surgical treatment for advanced disease is not always possible and adjuvant therapy may be required.
The therapeutic options for patients with inoperable vulvar cancers include chemoradiation [6] [7] [8] [9] [10] [11] [12] [13] and neoadjuvant chemotherapy [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The goal of these therapies being the reduction of tumor volume to allow effective surgical and/or radiation treatment. Multiple chemotherapy agents have been used in the treatment of advanced disease, without identification of an optimal chemotherapeutic regimen to induce disease regression [24] . In recent years, chemotherapy with platinum compounds, such as carboplatin, and paclitaxel has been shown to have some activity against vulvar cancer [21] . Both carboplatin and paclitaxel are used in conjunction for the treatment of ovarian and endometrial cancers, but have not been explored in the treatment of vulvar carcinoma. In the present report, we describe our experience with neoadjuvant carboplatin/paclitaxel chemotherapy in three patients with locally advanced squamous cell vulvar cancer. 
Management and Outcome
All three patients presented above where diagnosed with locally advanced, inoperable squamous cell carcinoma of the vulva. Different treatment options were discussed with each patient and all three women decided to undergo neoadjuvant chemotherapy with paclitaxel 175mg/m 2 and carboplatin (area under the curve, AUC, 5) every 3 weeks. Disease status was evaluated clinically and radiologically at baseline and following completion of 3 and 6 cycles of chemotherapy.
After three cycles of neoadjuvant chemotherapy, all of them presented with partial response with unchanged lymphadenopathy. All, except Patient 2 underwent additional cycles of chemotherapy, which yielded the following outcomes.
Three cycles of chemotherapy resulted in a 50% mass reduction as well as decreased lymph nodes size in Patient 1. After an additional three cycles, complete remission of the tumor with no evidence of malignancy on repeat PET scan was observed ( Figure 2 ). Three months later, an approximate 1 cm small, firm, mobile right vulvar nodule was palpated by the patient and confirmed to be recurrence of disease on biopsy. The patient underwent three cycles of chemotherapy with paclitaxel and carboplatin followed by radical wide local excision. Pathology of the surgical specimen demonstrated invasive squamous cell carcinoma with free margins. Three years after completion of her therapy, the patient noted right sided groin swelling which was confirmed to be recurrence of her vulvar cancer and is currently being treated with carboplatin and paclitaxel chemotherapy regimen.
Patient 2 received four cycles of neoadjuvant chemotherapy. Clinical exam demonstrated more than 50% reduction in tumor size after three cycles of chemotherapy. Due to significant reduction of the size of her tumor after the fourth cycle, the patient decided to discontinue treatment and ultimately was lost to follow-up.
The tumor size in Patient 3 was negligible compared to the other four women, as all three of her exophytic lesions were excised. However, based on the pathology of the lesions and evidence of malignancy on CT scan, the patient received chemotherapy. After the completion of six chemotherapy cycles complete remission was achieved based upon clinical exam and negative PET scan and currently she is disease free after ten months of follow up.
Chemotherapy
Discussion
Optimal management of locally advanced, inoperable vulvar cancer is a controversial and often debated topic. This has led to the establishment of different treatment modalities, some of which include primary chemoradiation [7, 10] and neoadjuvant chemotherapy [24] . The intentd of these therapies is being reduction of disease to allow less radical surgery and decreased toxicity.
In 1990 Shimizu et al. [19] were the first to report that a neoadjuvant regimen of bleomycin, vincristine, mitomycin C, and cisplatin resulted in complete remission in a 57 year old woman with stage IV squamous cell vulvar cancer after three cycles of chemotherapy. Since then, other studies have demonstrated varying success rates in decreasing tumor burden with different chemotherapy regimes.
A phase II clinical trial by the European Organization for Research and Treatment of Cancer (EORTC) assessed disease response to treatment with a combination of bleomycin, lomustine and methotrexate in patients with primary (18 patients) or recurrent (10 patients) vulvar carcinoma not amenable to standard radical vulvectomy [14] . Of the 28 patients enrolled in the study, 67% showed an objective response with a decrease in tumor size. A follow up trial with modification of the chemotherapy regimen resulted in a decrease in tumor size in 56% of patients [23] . Among the 25 patients treated with neoadjuvant chemotherapy, 12 partial and 2 complete responses were observed.
After the initial promising results, Benedetti-Panici [16] evaluated similar combination chemotherapy with bleomycin, methotrexate and cisplatin substituted for lomustine The study demonstrated a 10% partial response with a 33% pathological down staging rate and a 3 year survival rate of 24%. However, 79% of cases still required radical surgery, suggesting that neoadjuvant chemotherapy did not offer any substantial benefit to the surgery alone.
On the other hand, Geisler et al. [15] treated 14 patients with advanced vulvar cancer involving the anal sphincter and/or urethra with neoadjuvant chemotherapy consisting of either cisplatin/5 FU or cisplatin alone. Of the patients treated with cisplatin/5 FU, all showed at least a partial response to therapy that allowed for conservation of the anal sphincter and/or urethra. In contrast, the patients treated with cisplatin alone had no measurable disease response. Further evaluation of the role of cisplatin based neoadjuvant therapy in decreasing tumor burden to allow for less radical surgical resection was performed in a study done by Aragona et al. [22] . Their group described four different regimens. 5-fluorouracil/cisplatin, cisplatin/paclitaxel, cisplatin/paclitaxel/5-fluorouracil and cisplatin/ vincristine/bleomycin. 33 patients completed the proposed treatment schemes and 30 patients were assessed for radical surgery. Partial response was seen in 90.9% of the patients (30 out of 33) and 27 patients had undergone radical surgery. After a median follow-up of 49 months, 24 of the 27 patients were without disease and they concluded that neoadjuvant chemotherapy increases the surgical feasibility in select cases and encourages adjacent organ preservation. Weekly administration of paclitaxel (60mg/ m 2 ) and carboplatin (AUC of 2.7) showed limited clinical benefit in 6 patients with vulvar squamous cell cancer [17] . Raspagliesi et al. treated 10 patients with stage III and IV locally advanced squamous cell carcinoma of the vulva with 3 courses of paclitaxel-ifosfamide-cisplatin or paclitaxel- cisplatin and showed 80% clinical response rate (1 case with complete remission, 2 with persistent carcinoma in situ and 6 invasive cancer cases with tumor shrinkage of more than 50%). Nine of these patients subsequently underwent radical local excision or radical partial vulvectomy and bilateral inguino-femoral lymphadenectomy [25] .
Other studies (Table 1) including the current case series have shown that cisplatin or carboplatin in combination with topotecan [20] or paclitaxel/taxotere [26] demonstrated activity without significant toxicity in the neoadjuvant setting. A phase II trial of targeted therapy with erlotinib (150mg by mouth daily for 28-42 days before definite treatment with surgery or chemoradiation) demonstrated a 27.5% response rate in 41 patients with a 13.2 weeks progression free survival [18] .
Our results showed objective response to neoadjuvant chemotherapy consisting of paclitaxel and carboplatin in patients with locally advanced vulvar cancer. However, there are significant limitations. First, there were only three patients presented here. Second, the role of other chemotherapy agents should also be evaluated. For firm conclusions to be made, randomized clinical trials are needed.
In conclusion; despite limited number of the patients included in this and previous studies, these encouraging results should provide the foundation for prospective international trials, perhaps comparing chemoradiation with neoadjuvant chemotherapy (platinum/paclitaxel) plus targeted therapy (erlotinib) in patients with locally advanced squamous cell carcinoma of the vulva not amenable to surgery or chemoradiation. 
